Latest News

January 2016
Sandexis complete their 50th due diligence, third party review

January 2016
Sandexis / DNDi publish neglected tropical disease (NTD) open-access
manuscript in J. Med. Chem.

December 2015
Sandexis / University of Sheffield / Peakdale collaboration for the
discovery of ADM2 antagonists
has received funding from the
Wellcome Trust Seeding Drug Discovery initiative 

November 2015
Gavin visits Japan as part of the DNDi / GHIT collaboration

November 2015
Karl attending the 1st RSC / SCI symposium on Fibrosis in UK

October 2015
Sandexis celebrates 4 year anniversary

May 2015
Sandexis publish a review:
Small-molecule anti-inflammatory drug patents for the treatment of asthma 2013-2014

April 2015
Sandexis supply medicinal chemistry services to Calchan Ltd.
Karl will be consultant Director of Medicinal Chemistry for the
London based biotech.

February 2015
Karl and James are lecturing the MSc Drug Design course at
University of Kent, Canterbury

Sandexis LLP is a partnership of highly experienced PhD medicinal and computational chemists working at the cutting edge of modern medicinal chemistry.  We have more than 60 years of collective experience at Pfizer and Merck, encompassing the delivery of 15 clinical candidates across multiple disease areas.

We provide the following medicinal and computational chemistry design services:
Molecular Design: hit, lead and candidate identification
Computational Chemistry: bespoke support and packages
Project Management: integrated drug discovery
Scientific Writing: proposal writing and manuscript preparation
Consultancy: diligence, project reviews, expert witness and literature searches
Training: drug discovery, medicinal and computational chemistry

LinkedIn  Sandexis Medicinal Chemistry Ltd 2015
Company No. 07767700
Postal address: Innovation House, Discovery Park, Ramsgate Road, Sandwich, Kent, CT13 9ND, UK
Business registered address: 45 Queen Street, Deal, Kent, CT14 6EY, UK